Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Biontech Se ADR (NQ: BNTX )

91.32 -2.03 (-2.17%)
Streaming Delayed Price Updated: 11:05 AM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 169,854
Open 92.85
Bid (Size) 91.26 (1)
Ask (Size) 91.38 (2)
Prev. Close 93.35
Today's Range 90.75 - 93.23
52wk Range 85.21 - 125.83
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
BioNTech Se (BNTX) Q1 2024 Earnings Call Transcript
BNTX earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
BNTX Stock Earnings: BioNTech Misses EPS, Misses Revenue for Q1 2024
BNTX stock results show that BioNTech missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
-18.71%
-18.71%
1 Month
+2.25%
+2.25%
3 Month
-2.17%
-2.17%
6 Month
-8.41%
-8.41%
1 Year
-15.48%
-15.48%

More News

Read More
What's Going With BioNTech Stock On Monday?
Via Benzinga
BioNTech Slides After Reporting Losses As Covid Vaccine Sales Take A Hit
Via Investor's Business Daily
Exposures COVID-19
BioNTech Reports Downbeat Earnings, Joins Medical Properties Trust And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Wall Street Looks To Extend Rally Amid Caution Over Fed Speeches, More Earnings: Why This Analyst Thinks Bull Market Is Still 'Quite Young'
Via Benzinga
Topics Economy
Exposures Interest Rates
Assessing BioNTech: Insights From 11 Financial Analysts
Via Benzinga
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
From BioNTech SE
Via GlobeNewswire
GSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Via Benzinga
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures COVID-19 Financial Intellectual Property
What's Going On With Pfizer Stock On Thursday?
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Cracking The Code: Understanding Analyst Reviews For BioNTech
Via Benzinga
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Via Benzinga
Topics Stocks
Exposures US Equities
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
From BioNTech SE
Via GlobeNewswire
Bill Gates Called For A 'Universal Flu Vaccine,' Now The CDC Director Says The Organization Is 'Activated' After Issuing Bird Flu Alert
Via Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Via InvestorPlace
Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer
From BioNTech SE
Via GlobeNewswire
CureVac, GS Partner Release Data On Influenza Vaccine Study
Via Benzinga
The 3 Best Bargain Stocks to Buy in Q2 2024
Via InvestorPlace
3 Biotech Stocks to Buy for the Next Bull Run: March 2024
Via InvestorPlace
BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials
Via Benzinga
Exposures COVID-19
Stocks Quietly Higher As Central Bank Wraps Up Meeting
Via Talk Markets
Topics Economy
Exposures Interest Rates
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.